Boston, MA -- (SBWIRE) -- 04/04/2014 -- GBI Research, the leading business intelligence provider, has released its latest research, "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool", which provides in-depth insights into the Non-Small Cell Lung Cancer (NSCLC) indication. The report provides an estimation of the market size for 2012 along with market forecasts until 2019 for the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, clinical trial analysis (including failure rates), pipeline analysis, and analysis of deals relevant to NSCLC. The NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer's dacomitinib and Novartis's LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

View Full Report Details and Table of Contents

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in Australia, China, India and Japan. It includes -

- A brief introduction to NSCLC, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms
- In-depth analysis of currently marketed drugs for NSCLC, including analysis of their safety, efficacy, treatment patterns and strengths and weaknesses, as well as a heat map comparing them in terms of safety and efficacy
- A comprehensive review of the pipeline for NSCLC, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period, analyzed on the basis of phase distribution, molecule type, program type, mechanisms of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials, by Phase, trial size, trial duration and program failure rate, for each molecule type
- Multi-scenario forecast data of the market to 2019, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth
- Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies
- Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013
- Squamous Cell Carcinoma - Pipeline Review, H1 2013
- Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2013
- Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2013
- Ophthalmology Therapeutics Market in Asia-Pacific to 2019 - High Unmet Need and Moderate Short Term Prospects Focus Attention on Early Stage Activity
- Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
- Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth
- Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2013